HOME >> MEDICINE >> NEWS
IgG treatment during pregnancy reduces severity of rare, recurring liver condition in newborns

CHICAGO --- Treatment with high-dose immunoglobulin G (IgG) during pregnancy lessens the severity of hemochromatosis (NH), a rare, devastating gestational disease with abnormal iron accumulation in the liver and severe liver injury that almost always results in fetal death or acute liver failure in newborns.

In an article in the Nov. 6 issue of The Lancet, researchers Peter F. Whitington, M.D., and Judith U. Hibbard, M.D., described the effectiveness of treating mothers with IgG in reducing liver injury in babies with recurrent NH.

Whitington, a noted authority on liver disease, is professor of pediatrics at Northwestern University Feinberg School of Medicine, Children's Memorial Hospital. Hibbard is professor of maternal-fetal medicine, University of Illinois Chicago and held a similar position at the Pritzker School of Medicine, University of Chicago, during the course of the study.

One of the most devastating aspects of NH to affected families is that after a woman has had one baby with the disorder, her risk for recurrence of NH in another child is 80 percent. A woman may have unaffected children before having the first one with NH. After that, most or all pregnancies end with fetal death or a child born with NH.

Currently, there is no test to determine if a pregnancy will be affected, and there is no effective approach to prenatal diagnosis of NH. The best advice available to date for such women is to avoid pregnancy.

Until now, the cause of NH has been unknown. Whitington hypothesized that it is an alloimmune disease based on its unusual pattern of recurrence, which is similar to the known alloimmune diseases hydrops fetalis due to Rh incompatibility and neonatal alloimmune thrombocytopenia.

Treatment with IgG has been found effective in the treatment of these alloimmune blood disorders, so Whitington proposed its use in NH.

The positive results of the current study provide support for the th
'"/>

Contact: Elizabeth Crown or Kathleen Ellis
e-crown@northwestern.edu
312-503-8928
Northwestern University
9-Nov-2004


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Chronic pain treatments more effective when taken together, new study shows
3. Brain activity prior to treatment flags vulnerability to antidepressant side effects
4. Cultural and social factors influence prostate cancer treatment
5. Research offers hope of new treatments for liver damage
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Stanford patient is first to test new treatment for peripheral arterial disease
8. Scientist works on innovative treatments for brain tumors
9. Blacks less likely to get expensive, newer heart treatments
10. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
11. Study examines lessons learned at Africas first public antiretroviral treatment clinic

Post Your Comments:
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... for Women’s Cancer announce today that Dr. Beth ... of the Claudia Cohen Research Foundation Prize for Outstanding ... the Society of Gynecologic Oncology 46th Annual Meeting on ... of the Cedars-Sinai Women’s Cancer Program at the Samuel ...
(Date:3/29/2015)... 29, 2015 Youth Villages will participate ... Oregon to assess the feasibility of implementing a Pay ... behavioral problems and their families. , Third Sector Capital ... that will be provided technical assistance throughout 2015 toward ... six other national awardees chosen by Third Sector. The ...
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... Take a bite of warm, gooey ... Acids tumble into the stomach, ready to break down ... lets these acids run amok, triggering a burning sensation ... More than 60 million Americans have heartburn at least ... starts, and how it can be stopped. , Heartburn ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... clinic that offers urgent care in Manhattan, recently commemorated ... urgent care facility in Manhattan. In addition to 24-hour ... to ER facilities. , At this time, Emergency ... treatments for abdominal pain, asthma, chest pain, eye injuries, ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
(Date:3/29/2015)...  Three-month paliperidone palmitate, an investigational atypical antipsychotic, ... in patients with schizophrenia, according to a new ... the Journal of the American Medical ... of the study served as the basis for ... three-month paliperidone palmitate injection to treat schizophrenia in ...
(Date:3/27/2015)... YORK , March 27, 2015 BioCorRx, ... Santa Ana, California is a healthcare ... for which is estimated at $22 billion in the U.S. ... the use of FDA-approved Naltrexone in a specially compounded form ... Australia and New Zealand ...
(Date:3/27/2015)... , March 27, 2015 Across the ... to meeting challenges in clinical development, market education, and ... regulations, the Medical Affairs function is expected to increase ... markets. According to research by benchmarking ... have a group dedicated to Medical Affairs. Among companies ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
Cached News: